Clinical Trials for Neurofibromatosis-2
Clinical trials are research studies conducted in an effort to improve overall patient health and care.
Each trial involves running supervised tests to determine the effectiveness and safety of new drugs, procedures and/or devices with the aim of answering scientific questions about a disease or condition.
Risks and side-effects are also evaluated during these trials with results ranging from being unpleasant, with side effects such as headaches, to more serious or even life-threatening risks.
A clinical trial may be separated into phases, or steps, with each step designed to answer a separate research question. This maybe reflected in the trial name.
A brief description of each phase:
- Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
- Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
- Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and safety.
- Phase IV: These studies monitor long-term side effects after the treatment has been marketed.
Clinical Trials data for Neurofibromatosis-2 is grouped into the following categories:-
The format for each of the following is:
- The name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
- followed by a list of drug/s, if any, used in the trial
ClinicalTrials.gov has listed the following trials for Neurofibromatosis-2:
The trial data on this page has been sourced from